Anaphylaxis is a sudden, rapid and life-threatening allergic reaction 

An anaphylactic reaction occurs when a person is exposed to an allergen, such as certain foods, medications, or insect stings. Anaphylaxis triggers a systemic response that can rapidly escalate and, if left untreated, may be life-threatening.

The need for an alternative treatment for anaphylaxis

Epinephrine, also known as adrenaline, is the primary treatment for anaphylaxis. However, it is a highly unstable compound that degrades quickly. Delayed or none administration of epinephrine increases the risk of fatal anaphylactic reactions. Injection anxiety, especially in children, and worries about the improper use of autoinjectors are exacerbating this issue.

Orexo is breaking new ground in the area of anaphylaxis

Orexo has developed OX640, an epinephrine product with nasal delivery, utilizing its proprietary AmorphOX® drug delivery platform. AmorphOX is a powder-based technology that ensures rapid onset and reduces the epinephrine's sensitivity to temperature fluctuations, enhancing the handling and storage of the product. OX640 is a needle-free option, and its compact size makes it highly portable. Additionally, it is devoid of antioxidants and preservatives, which are known to cause allergic reactions.

OX640 has already been tested in a phase 1 clinical study with healthy volunteers. Orexo is currently exploring partnerships for continued development and commercialization.